XML 84 R72.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaborations and grants (Details) |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jan. 02, 2011 deliverable | Oct. 31, 2017 USD ($) | Nov. 30, 2014 USD ($) | Jan. 31, 2014 USD ($) | Nov. 30, 2011 USD ($) compound | Dec. 31, 2017 USD ($) deliverable | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($)
Collaborations and grants |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  | $ 0 | $ 900,000 | $ 2,200,000
Minimum |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Term of grant program |  |  |  |  |  | 2 years |  |
Maximum |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Term of grant program |  |  |  |  |  | 5 years |  |
Collaboration agreement | Development event milestones |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Collaboration revenue recognized |  | $ 20,000,000 | $ 10,000,000 | $ 7,500,000 |  |  |  |
Collaboration agreement | Roche and SMA Foundation |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Number of compounds in preclinical development | compound |  |  |  |  | 3 |  |  |
Deferred revenue |  |  |  |  | $ 30,000,000 |  |  |
Number of significant deliverables | deliverable |  |  |  |  |  | 2 |  |
Research period for applying technology |  |  |  |  | 2 years |  |  |
Collaboration revenue recognized |  |  |  |  |  | $ 20,300,000 | 400,000 | $ 600,000
Collaboration agreement | Roche and SMA Foundation | Development event milestones |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Additional consideration receivable upon achievement of specified events |  |  |  |  |  | 135,000,000 |  |
Collaboration agreement | Roche and SMA Foundation | Sales milestones |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Additional consideration receivable upon achievement of specified events |  |  |  |  |  | 325,000,000 |  |
Early stage collaboration and discovery agreements |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  | $ 0 | 0 |
Number of significant deliverables | deliverable | 2 |  |  |  |  |  |  |
Collaboration revenue recognized |  |  |  |  |  |  | $ 1,800,000 |
Early stage collaboration and discovery agreements | Minimum |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Research period for applying technology |  |  |  |  |  | 3 years |  |
Early stage collaboration and discovery agreements | Maximum |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Research period for applying technology |  |  |  |  |  | 4 years |  |
Early stage collaboration and discovery agreements | Development event milestones |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Additional consideration receivable upon achievement of specified events |  |  |  |  |  | $ 143,000,000 |  |
Early stage collaboration and discovery agreements | Sales milestones | Maximum |  |  |  |  |  |  |  |
Collaborations and grants |  |  |  |  |  |  |  |
Additional consideration receivable upon achievement of specified events |  |  |  |  |  | $ 252,000,000 |  |

X
- Definition Represents the amount of potential additional consideration receivable under contractual agreements. + References No definition available. + Details
Name: | ptct_CollaborationAgreementContingentConsiderationReceivable
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the number of compounds included in preclinical development. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment
Namespace Prefix: | ptct_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of significant deliverables under a contractual agreement. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsNumberOfSignificantDeliverables
Namespace Prefix: | ptct_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the research period for applying discovery technology. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology
Namespace Prefix: | ptct_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the term of the grant program. + References No definition available. + Details
Name: | ptct_TermOfGrantProgram
Namespace Prefix: | ptct_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_RevenueFromGrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ptct_RocheAndSmaFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ptct_MilestoneAxis=ptct_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptct_CollaborationAndDiscoveryAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |